Evidence map›Paper›PMID 39896279›Full record

ArticleMaterials today. Bio2025

Redox-responsive metal-organic framework nanocapsules enhance tumor chemo-immunotherapy by modulating tumor metabolic reprogramming.

Yuman Dong, Jieru Li, Yiwei Dai, Xinyu Zhang, Tao Wang, Bin Zhao, Wenbo Liu, Li Chen, Shaopei Yang, Pengcheng Du and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yuman DongCuiying Biomedical Research Center, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730030, China.
Jieru LiThe Second Clinical Medical College, Lanzhou University, Lanzhou, 730030, China.
Yiwei DaiThe Second Clinical Medical College, Lanzhou University, Lanzhou, 730030, China.
Xinyu ZhangThe Second Clinical Medical College, Lanzhou University, Lanzhou, 730030, China.
Tao WangThe Second Clinical Medical College, Lanzhou University, Lanzhou, 730030, China.
Bin ZhaoThe Second Clinical Medical College, Lanzhou University, Lanzhou, 730030, China.
Wenbo LiuThe Second Clinical Medical College, Lanzhou University, Lanzhou, 730030, China.
Li ChenDepartment of Orthopaedics, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730030, China.
Shaopei YangCollege of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, 730000, China.
Pengcheng DuCollege of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, 730000, China.
Zuoyi JiaoDepartment of General Surgery, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730030, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy, particularly immune checkpoint blockade (ICB), has opened the era of modern oncology, offering significant promise for modern oncology. However, the efficacy of immunotherapy is frequently curtailed by the immunosuppressive tumor microenvironment (ITM), a milieu shaped by tumor metabolic reprogramming. Herein, a novel tumor microenvironment-responsive nanocapsules (DNMCs) were developed that simultaneously modulate tumor metabolism and the ITM to enhance the effectiveness of chemo-immunotherapy. DNMCs consist of an acidic and redox-sensitive metal-organic framework (MOF) encapsulating Doxorubicin (DOX) and the indoleamine-2,3-dioxygenase1 (IDO1) inhibitor NLG919. In the tumor microenvironment, DNMCs degrade, rapidly releasing DOX and NLG919. DOX induces immunogenic cell death (ICD), while NLG919 regulates amino acid metabolism by modulating IDO1 activity, thereby reversing the immunosuppressive of ITM. Consequently, DNMCs elicit effective anti-tumor immune responses, characterized by an increased density of tumor-infiltrating CD8

Indexed as

Immunogenic cell deathImmunosuppressive tumor microenvironmentMetal organic frameworkTumor amino acid metabolismTumor microenvironment triggered

Identifiers

PMID39896279
PMCPMC11786678

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.